Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience
Authors:
- 30 January 2022
- journal article
- research article
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (4) , 2845-2848
Abstract
Background Hereditary transthyretin amyloidosis (ATTRv) is a treatable multisystem disorder with prevalent peripheral nervous system impairment. Besides neurophysiological measures, there are few markers to monitor disease progression. Neurofilament light chain (NfL) has recently been considered a sensitive biomarker for neuroaxonal damage in this setting. Objective To evaluate NfL levels in a cohort of ATTRv patients and pre-symptomatic carriers and correlate the serum concentrations with other markers of disease severity. Methods We analysed NfL serum from 17 ATTRv patients or carriers and 26 controls. An exhaustive clinical and instrumental evaluation was performed in all patients. Results NfL levels were significantly higher in ATTRv cases when compared with controls. A significant correlation was found between NfL values and NIS scale, Sudoscan values from feet, interventricular septum thickness, and Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) questionnaire. Conclusion We confirm that NfL is a reliable and promising biomarker to evaluate the ATTRv severity and monitor its progression.Keywords
This publication has 10 references indexed in Scilit:
- Progressive brachial plexus enlargement in hereditary transthyretin amyloidosisJournal of Neurology, 2021
- Comparison of SimoaTM and EllaTM to assess serum neurofilament‐light chain in multiple sclerosisAnnals of Clinical and Translational Neurology, 2021
- Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated AmyloidosisNeurology, 2021
- ATTRv amyloidosis Italian Registry: clinical and epidemiological dataAmyloid, 2020
- Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient CareTherapeutics and Clinical Risk Management, 2020
- Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathyAmyloid, 2020
- Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosisJournal of the Peripheral Nervous System, 2019
- Neurofilament light chain as a biomarker in neurological disordersJournal of Neurology, Neurosurgery & Psychiatry, 2019
- Sudoscan in the evaluation and follow-up of patients and carriers with TTR mutations: experience from an Italian CentreAmyloid, 2018
- Neurofilaments as biomarkers in neurological disordersNature Reviews Neurology, 2018